Meda’s US$10bn recommended takeover by Mylan



Rothschild  Global Advisory and AC ADV INC used its in-depth understanding of the global pharmaceutical sector, and its relationship with Meda, the international specialty pharmaceutical company, headquartered in Sweden, to advise the Meda Board on their recommended takeover by Mylan

The combination created a strong global player in diversified pharmaceuticals with an expansive portfolio of branded and generic medicines and a strong, growing portfolio of over-the-counter (OTC) products. It represented an excellent outcome for both Meda and their shareholders.

Seeking potential targets for acquisition, Mylan had previously identified Meda as an attractive and complementary company. Whilst a previous takeover offer in 2014 was rejected, the two companies have since developed significantly; acquiring new businesses into their portfolios and in 2015 the combination presented an even stronger business fit.

This transaction continued Rothschild Global Advisory's strong relationship with Meda, having advised on their acquisition of Rottapharm | Madaus in 2014 and the disposal of Euromed (a subsidiary) in 2015.

The combination of Mylan and Meda represented the largest European pharma takeover in five years and the largest deal in the sector for a Swedish company since 1998.  It created a diversified global pharmaceutical leader with an expansive portfolio and achieved critical mass in key segments, thus offering greater opportunities for growth. The combined company gained a balanced global footprint with significant scale in key geographic markets, particularly the U.S. and Europe. The acquisition of Meda also provided Mylan with enhanced scale in a number of growing and attractive emerging markets including China, Southeast Asia, Russia, the Middle East and South America.

Rothschild Global Advisory provided comprehensive advice to Meda on its consideration of the offer and within a tight timescale led complex negotiations between the two companies, in order to ensure the best value for Meda shareholders.